See more of the story

Boston Scientific expects its underlying business to remain robust for the rest of the year, but an off-kilter economy could dampen growth.

The medical device maker, with sizable operations in Minnesota, edged expectations with its second-quarter sales and earnings. But the Massachusetts-based company lowered its 2022 revenue expectations with sales growth of between 6.5 to 7.5%, down from its earlier guidance of 7 to 9%.

However, Boston Scientific boosted guidance for organic sales, which measures the company's true growth by controlling for one-time expenses or events, such as foreign currency exchange rates that are expected to pinch over reported sales. It now projects a gain of between 8 to 9%, up from its earlier organic sales forecast of 6.5 to 8.5% growth for the year.

"The macroeconomic environment continues to be challenging," said Mike Mahoney, Boston Scientific's chief executive, in a morning conference call.

He cited issues including foreign currency exchange rates, supply chain challenges, staffing issues at hospitals and a shortage of contrast dye.

Hospital staffing issues and the contrast dye shortage have delayed some procedures. Contrast dye is injected into patients for imaging tests such as CT scans.

For the second quarter, Boston Scientific reported earnings per share of $0.44, topping the consensus estimate of $0.42.

The company grew sales by 5.4% to $3.24 billion, slightly above expectations of $3.22 billion in revenue for the quarter.

In a report on the results Robbie Marcus, an analyst with J.P. Morgan, called the numbers "solid" and added "all told, today's report met/exceeded our bullish expectation."

The company's stock closed up more than 6% Wednesday.

Boston Scientific's largest unit, cardiovascular devices, accounts for 61.5% of total revenue. Cardiovascular sales were up 6% for the quarter.

The company saw its biggest sales gain in urology and pelvic health products, with an increase of 13.4% in revenue, while neuromodulation saw sales decline 3.4% for the quarter.

Boston Scientific has about 8,400 employees in Minnesota compared to 2,300 employees in Massachusetts.